Completed PHASE3 INTERVENTIONAL 3-arm NCT01808118

Continuing Versus Withdrawing Adalimumab in Maintaining Remission in Non-Radiographic Axial Spondyloarthritis

A Multicenter, Randomized, Double-Blind, Study Comparing the Efficacy and Safety of Continuing Versus Withdrawing Adalimumab Therapy in Maintaining Remission in Subjects With Non-Radiographic Axial Spondyloarthritis

Sponsor: AbbVie

Conditions Axial Spondyloarthritis

Interventions Placebo adalimumab

Updated 8 times since 2017 Last updated: Apr 30, 2018 Started: Apr 16, 2013 Primary completion: Feb 21, 2017 Completion: Apr 14, 2017

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE3 trial investigates Axial Spondyloarthritis and is currently completed. AbbVie leads this study, which shows 8 recorded versions since 2013 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

8 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE3
Jan 2021 — Jul 2024 [monthly]

Completed PHASE3
Jun 2018 — Jan 2021 [monthly]

Completed PHASE3
May 2018 — Jun 2018 [monthly]

Completed PHASE3

Phase: PHASE4 → PHASE3

▶ Show 3 earlier versions

Mar 2017 — May 2018 [monthly]

Completed PHASE4

Status: Active Not Recruiting → Completed
Feb 2017 — Mar 2017 [monthly]

Active Not Recruiting PHASE4
Jan 2017 — Feb 2017 [monthly]

Active Not Recruiting PHASE4

First recorded

Apr 2013

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

AbbVie

Data source: AbbVie

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

No location information available.